Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center

The Journal of Nuclear Medicine

article

Ken Herrmann¹  Luca Giovanella²  Andrea Santos³  Jonathan Gear⁴  Pinar Ozgen Kiratli⁵  Jens Kurth⁶  Ana M. Denis-Bacelar⁷  Roland Hustinx⁸  Marianne Patt⁹  Richard L. Wahl^1,10  Diana Paez^1,11  Francesco Giammarile^1,11  Hossein Jadvar^1,12  Neeta Pandit-Taskar^1,13  Munir Ghesani^1,14  Jolanta Kunikowska^1,15 

[1] Department of Nuclear Medicine, University of Duisburg-Essen;Clinic for Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland;Department of Nuclear Medicine, Hospital Cuf Descobertas;Joint Department of Physics, Royal Marsden NHS Foundation Trust;Department of Nuclear Medicine, Hacettepe University;Department of Nuclear Medicine, Rostock University Medical Center;National Physical Laboratory;Division of Nuclear Medicine and Oncological Imaging, University Hospital of Liège;Department for Nuclear Medicine, University Hospital Leipzig;Department of Radiology, Washington University School of Medicine;Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, Department of Nuclear Sciences and Application, International Atomic Energy Agency;Division of Nuclear Medicine, Department of Radiology, University of Southern California;Department of Radiology, Memorial Sloan Kettering Cancer Center;Diagnostic, Molecular & Interventional Radiology, Icahn School of Medicine at Mount Sinai;Nuclear Medicine Department, Medical University of Warsaw

关键词: theranostics;    radionuclide theranostics;    nuclear medicine;    PSMA;    PRRT;   

DOI  :  10.2967/jnumed.122.264321

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

The theranostics concept using the same target for both imaging and therapy dates back to the middle of the last century, when radioactive iodine was first used to treat thyroid diseases. Since then, radioiodine has become broadly established clinically for diagnostic imaging and therapy of benign and malignant thyroid disease, worldwide. However, only since the approval of SSTR2-targeting theranostics following the NETTER-1 trial in neuroendocrine tumors, and the positive outcome of the VISION trial has theranostics gained substantial attention beyond nuclear medicine. The roll-out of radioligand therapy for treating a high-incidence tumor such as prostate cancer requires the expansion of existing and the establishment of new theranostics centers. Despite wide global variation in the regulatory, financial and medical landscapes, this guide attempts to provide valuable information to enable interested stakeholders to safely initiate and operate theranostic centers. This enabling guide does not intend to answer all possible questions, but rather to serve as an overarching framework for multiple, more detailed future initiatives. It recognizes that there are regional differences in the specifics of regulation of radiation safety, but common elements of best practice valid globally.

【 授权许可】

CC BY